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Abstract
Background: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in
the progress of adult leukemia. The role of miRNAs in pediatric leukemia still needs to be established. The purpose of this
study was to investigate the aberrantly expressed miRNAs in pediatric acute leukemia and demonstrate miRNA patterns
that are pediatric-specific and prognostic parameter-associated.
Methodology/Principal Findings: A total of 111 pediatric bone marrow samples, including 99 patients and 12 normal
donors, were enrolled in this study. Of those samples, 36 patients and 7 normal samples were used as a test cohort for the
evaluation of miRNA profiling; 63 pediatric patients and 5 normal donors were used as a validation cohort to confirm the
miRNA differential expression. Pediatric ALL- and AML-specific microRNA expression patterns were identified in this study.
The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly
expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly
different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3
and M2 patients, respectively. Importantly, we identified a ‘‘miRNA cascade’’ associated with central nervous system (CNS)
relapse in ALL. Additionally, miRNA patterns associated with prednisone response, specific risk group, and relapse of ALL
were also identified.
Conclusions/Significance: There are existing pediatric-associated and prognostic parameter-associated miRNAs that are
independent of cell lineage and could provide therapeutic direction for individual risk-adapted therapy for pediatric
leukemia patients.
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Introduction
In recent years, a new class of small noncoding RNAs, ranging
from 19 to 25 nucleotides in size and named microRNAs
(miRNAs), was discovered and has been shown to regulate gene
expression at the transcriptional or post-transcriptional level [1,2].
The basic function of miRNAs is to reduce the steady-state protein
levels of targeted genes. Three primary mechanisms have been
proposed based on early observations and experiments involving
both siRNAs and miRNAs: translational repression, mRNA
cleavage, and transcriptional silencing. The specific consequences
of miRNA expression appear to depend on the level of
complementarity between the miRNA and the target. Most
animal miRNAs contain central regions that are non-complemen-
tary to their targets and act by suppressing the translation of the
target mRNA [3–6].
After the first finding that adult patients with chronic
lymphocytic leukemia (CLL) often have deletions or downregula-
tion of two miRNA genes miR-15 and miR-16 at 13q14 [7], it has
been well known that about 50% of the annotated human
miRNAs are located at fragile sites and genomic regions involved
in cancers [8], and that miRNA expressions are correlated with
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7826various cancers. All these observations suggest that miRNAs
function as both tumor suppressors and oncogenes [9,10].
Additionally, the expression profiling of miRNAs rather than
mRNAs has been shown to be a more accurate method of
classifying cancer subtypes [10]. Furthermore, cancer-specific
miRNA profiles associated with diagnosis, staging, progression,
prognosis, and response to treatment were identified in many
cancers [11,12]. In leukemia, microRNA expression signatures
associated with the cytogenetics and clinical outcome of adult
CLL, AML, and Hodgkin lymphoma were reported [13–18].
In comparison with the large number of adult-based studies, the
number of studies on the miRNA expression features and functions
in pediatric-on set leukemia is relatively low [19,20]. Mi et al. [21]
performed a genome-wide miRNA expression analysis on acute
leukemia samples and demonstrated that the expression signatures
from as few as two miRNAs could accurately discriminate ALL
from AML, and raised the possibility of using such lineage-
discriminatory miRNAs to develop a rapid and accurate diagnostic
test of ALL versus AML in the future. However, the possibility of a
more accurate diagnosis of acute leukemia based on miRNAs in the
pediatric population remains to be realized. Similarly, it remains to
be determined whether distinct expression signatures exist for
prognostic parameters, including prednisone response and specific
risk group, and for the association of specific miRNAs with the risk
of relapse in pediatric leukemia.
Materials and Methods
Patients and Clinical Information
A total of 111 pediatric bone marrow samples, including 99
patients and 12 normal donors, from the First and Second
Affiliated Hospital of Sun Yat-sen University were enrolled in this
study according to the following criteria: age ,14 years at
diagnosis; patients with primary ALL or AML; and untreated.
Among those samples, 36 patients and 7 normal samples were
used as a test cohort for the evaluation of miRNA profiling. The
other 63 pediatric patients (31 ALL and 32 AML) and 5 normal
donors were used as a validation cohort to confirm the miRNA
differential expression. Patients’ characteristics, such as presenting
age, sex, WBC count, FAB classification, immunological classifi-
cation, etc., were available for test cohort and validation cohort
patients (see Table 1, Table 2). Written informed consent for
biological studies was obtained from all the patients analyzed. The
study was approved by the Ethics Committee of the affiliated
hospitals of Sun Yat-sen University.
RNA Extraction and MicroRNA Microarray Experiments
Total RNA was isolated with Trizol (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. The miRNA
microarray analyseswere performed with miRNA microarray
chips (CapitalBio, Beijing, China) containing 743 probes in
triplicate, which corresponded to 576 human (including 122
predicted miRNAs sequences from a published reference
22), 238
rat, and 358 mouse mature miRNAs found in the miRNA
Registry (http://microrna.sanger.ac.uk/sequences/; miRBase8.2;
July 2006). Briefly, 4 mg of low-molecular weight RNA was labeled
with 59-phosphate-cytidyl-uridyl-cy3-39 (Dharmacon, Lafayette,
CO) using T4 RNA ligase (New England Biolabs, Ipswich, MA).
Hybridization was carried out at 42uC overnight, followed by two
consecutive washes with solutions of 0.2% SDS, 26SSC at 42uC
for 5 min and 0.2% SSC for 5 min at room temperature. Arrays
were scanned with a LuxScan
TM 10K-A laser confocal scanner
(CapitalBio) and the obtained images were then analyzed using
LuxScan 3.0
TM software (CapitalBio). All the data are MIAME
Table 1. Characteristics of test cohort.
Type of sample Characteristics Median (range) No. (%)
ALL (N=18) Age at diagnosis, y 5.4 (1–11)
Sex
Male 14 (77.8)
Female 4 (22.2)
WBC count, 6 610
9/L 51.6 (3.1–304)
Less than 20 11 (61.1)
20–50 4 (22.2)
50 or higher 3 (16.7)
FAB
L1 7 (38.9)
L2 8 (44.4)
L3 3 (16.7)
Risk group
HR 4 (22.2)
IR 10 (55.6)
SR 4 (22.2)
Relapse
&
ALL/including CNS
relapse
6 (33.4)/4 (22.2)
Without relapse 12 (66.6)
Prednisone response
Good response 12 (66.7)
Poor response 6 (33.3)
Immunophenotype
B 17 (94.4)
T 1 (5.6)
Cytogenetics
BCR/ABL 2 (11.1)
BCR/ABL negative 16 (88.9)
AML (N=18) Age at diagnosis, y 8.3 (2.5–13)
Sex
Male 9 (50.0)
Female 9 (50.0)
WBC count, 6 610
9/L 36.7 (3.4–83.8)
Less than 10 7 (38.9)
10–50 6 (33.3)
50 or higher 5 (27.8)
FAB
M1 4 (22.2)
M2 10 (55.6)
M3 4 (22.2)
Cytogenetics
AML1/ETO 7 (38.9)
PML/RARA 4 (22.2)
Both negative 7 (38.9)
Normal (N=7) Age at diagnosis, y 5.8 (1–13)
Sex
Male 4 (57.1)
Female 3 (42.9)
&With one year of clinical follow-up.
doi:10.1371/journal.pone.0007826.t001
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compliant database (ArrayExpress, GEO).
Date Analysis
Raw data were normalized using the median center tool for
genes in the Cluster 3.0 software. Differentially expressed miRNAs
were identified by the Significance Analysis of Microarrays (SAM,
available at http://www-stat.stanford.edu/,tibs/SAM/ index.
html). Array data were clustered using Cluster 3.0. Java TreeView
1.0 was used for tree visualization. Elimination criteria were
constructed to detect changes between the leukemia-induced and
control miRNA levels. First, the average signal-to-noise ratio
(SNR) was greater than two. Second, the adjusted ratios were
greater than 2 or less than 22 for inclusion. Third, statistical
significance was obtained from the SAM analysis with q,0.01.
Statistical Analysis
Fisher’s exact test, t-test, and chi-square were used to compare
baseline characteristics and average miRNA expression between
groups of patients, and between patients and controls. All reported
P values were two-sided and obtained using the SPSS software.
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time reverse transcriptase PCR (qRT-PCR)
was performed as previously described [23] and employed a
Hairpin-it
TM miRNA Real-Time PCR Quantitation Kit contain-
ing a stem-loop-like RT primer, miRNA specific PCR primer, and
the Molecular Beacon probe (GenePharma, Shanghai, China).
Briefly, RNA was reverse-transcribed to cDNA with an miRNA-
specific stem-loop-like RT primer, and the expression of each
miRNA relative to the normal control was determined using the
2
2DDCT method [24]. Comparative real-time PCR was performed
in triplicate and included no-template controls.
Target Genes Prediction
The target genes prediction was performed to meet both of the
following qualifications. First, the miRNA targets were analyzed by
using three algorithms, including TARGETSCAN (http://www.
targetscan.org/), PICTAR (http://pictar.bio.nyu.edu/), and miR-
Base (available at http://microrna.sanger.ac.uk/sequences/index.
shtml). Second, to reduce the number of false positives, only putative
target genes predicted by at least two of the programs were accepted.
Results
MicroRNA Expression Profiles in Pediatric ALL and AML
To investigate the expression profile of miRNA in pediatric
AML and ALL, we used a miRNA microarray to analyze the
miRNome expression in 36 newly diagnosed acute leukemia
samples and compared them with the mononuclear cells (MNC)
from the bone marrow of seven normal donors (Figure 1A and
Table 2. Characteristics of validation cohort.
Type of sample Characteristics Median (range) No. (%)
ALL (N=31) Age at diagnosis, y 9.5 (0–14)
Sex
Male 25 (80.6)
Female 6 (19.4)
WBC count, 6 610
9/L 65.7 (1.7–645)
Less than 20 20 (64.5)
20–50 7 (22.6)
50 or higher 4 (12.9)
FAB
L1 15 (48.4)
L2 14 (45.2)
L3 2 (6.4)
Risk group
HR 14 (45.2)
IR 9 (29.0)
SR* 5 (16.1)
Relapse
&
ALL/including CNS
relapse
3 (9.7)/3
(9.7)
Without relapse** 26 (83.9)
Prednisone response
Good response
# 17 (54.8)
Poor response 7 (22.6)
Immunophenotype
B 31 (100)
T 0 (0)
Cytogenetics
BCR/ABL 4 (12.9)
BCR/ABL negative 27 (87.1)
AML (N=32) Age at diagnosis, y 3.7 (0–14)
Sex
Male 23 (71.9)
Female 9 (28.1)
WBC count, 6 610
9/L 28.9 (2.5–292)
Less than 10 18 (56.3)
10–50 8 (25.0)
50 or higher 6 (18.7)
FAB
M1 5 (15.6)
M2 13 (40.6)
M3 8 (25.0)
M4 3 (9.4)
M5 3 (9.4)
Cytogenetics
AML1/ETO 5 (15.6)
PML/RARA 5 (15.6)
Both negative 22 (68.8)
Normal (N=5) Age at diagnosis, y 6.2 (2–11)
Sex
Male 3 (60.0)
Table 2. Cont.
Type of sample Characteristics Median (range) No. (%)
Female 2 (40.0)
*There were no enough total RNA left for three SR patients because they were
used for other miRNAs’ validation; &With one year of clinical follow-up;
** There were no enough total RNA left for two patients without relapse
because they were used for other miRNAs’ validation;
#There were no enough
total RNA left for seven good response patients because they were used for
other miRNAs’ validation.
doi:10.1371/journal.pone.0007826.t002
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7826Figure 1. Cluster analysis in pediatric ALL and AML and miRNA expression in pediatric ALL and AML validated with qRT-PCR using
the validation cohort. (A) The 182 top–ranked differentially expressed miRNAs in pediatric ALL; (B) The 131 top–ranked differentially expressed
miRNAs in the French-American-British (FAB) classification of pediatric AML; (C) MiR-100 expression in pediatric ALL and AML validation cohort
(p=0.000); (D) MiR-34a was up-regulated in pediatric ALL validation cohort (p=0.003); (E) MiR-146a was up-regulated in AML validation cohort
(p=0.046).
doi:10.1371/journal.pone.0007826.g001
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miRNAs that showed significant differences between the primary
ALL and normal samples, while 17 up-regulated and 18 down-
regulated miRNAs were significantly deregulated in primary AML
(Table 3) with criteria elimination. To validate these results, we
performed qRT-PCR for miR-100 (ALL=31 and AML=32,
Figure 1C), miR-34a (ALL=24, Figure 1D) and miR-146a
(AML=32, Figure 1E) using the validation cohort.
The results listed in Table 2 showed that the highly expressed
miRNAs in pediatric AML were miR-100, miR-125b, miR-335,
miR-146a,a n dmiR-99a, which were different from those
observed in adult AML cases [15,16,21]. The most represented
miRNAs in the pediatric AML samples were miR-100 and miR-
125b, which both had much lower expression levels in ALL. The
most highly expressed miRNAs in ALL were miR-128a, miR-
128b, miR-213, miR-210, miR-130b, miR-146a,a n dmiR-34a.O n l y
17 miRNAs showed similar expression profiles and were shared
by both ALL and AML. These results indicated that the
regulatory networks between pediatric ALL and AML could be
different.
To explore the relationship among the samples, as well as the
underlying patterns of miRNA ge n ee x p r e s s i o n ,w ep e r f o r m e da n
unsupervised hierarchical cluster analysis using the 576 human
mature miRNAs. Figure 1A showed the cluster of ALL. The
cluster of AML is shown in Figure 1B. The unsupervised
hierarchical clustering based on the expression of these sets of
genes in AML identified three groups that coincided precisely
with the phenotypic classification of the most common cytoge-
n e t i cs u b t y p e so fA M Ll i n e a g e ,M 1 ,M 2 ,a n dM 3 ,w h i c ha r e
based on the type of cell from which the leukemia developed and
its degree of maturity. As shown in Table 4,t h emiR-335 in M1,
the miR-126 in M2, and the miR-125b in M3 were significantly
up-regulated. These findings were validated with qRT-PCR
using the validation cohort (N=32) (Figure 2A and 2B).T h e
differential miRNA expression patterns suggested that the
miRNA cascade of FAB subtypes may serve as biomarkers for
the classification of pediatric AML. To further investigate the
relationship between miRNAs and cytogenetics, we analyzed
miR-125b in M3 patients with the validation cohort and found
that the expression of miR-125b was much higher in PML/RARA
positive patients than in PML/RARA negative patients, though
miR-125b was highly expressed in both groups (Figure S1A).
This result suggested that miR-125b is associated with PML/
RARA status. The correlation of miR-126 with cytogenetic AML1-
ETO in M2 patients was similar to miR-125b and PML/RARA in
M3 patients. Figure S1B showed that miR-126 expression in
AML1-ETO positive patients was slightly higher than in AML1-
ETO negative patients using the validation cohort. This implied
that miR-126 may be also associated with the prognosis of M2
patients.
Table 3. Differentially expressed microRNAs in pediatric AML
and ALL compared with the normal control.
MicroRNA Fold change compared with the normal control*
AML ALL
miR-100 24.41 0.75
miR-125b 12.37 1.16
miR-335 5.35 0.88
miR-146a 4.57 4.98
miR-99a 3.81 1.79
miR-34a 3.21 4.96
miR-210 3.12 4.72
miR-213 3.12 3.63
miR-181c 2.87 2.37
miR-146b 2.78 1.91
miR-126 2.69 2.09
miR-181a 2.55 2.33
miR-181d 2.48 3.06
miR-130a 2.43 2.17
miR-195 2.26 2.95
miR-181b 2.09 3.35
miR-222 2.00 1.33
miR-130b 1.32 3.67
miR-155 1.80 3.27
miR-17-3p 1.46 2.45
Let-7a 1.14 0.59
miR-15a 0.73 1.47
miR-16-1 0.92 1.25
miR-199a 1.37 0.23
miR-128b 1.27 3.69
miR-199b 1.22 0.22
miR-128a 1.17 3.70
miR-29a 1.07 0.47
miR-24 1.01 0.48
miR-18b 0.93 2.23
miR-28 0.82 2.34
miR-424 0.54 0.31
miR-331 0.49 2.41
miR-505 0.48 2.45
miR-150 0.47 0.99
miR-30e-3p 0.46 0.99
miR-142-3p 0.46 1.30
miR-197 0.45 1.30
miR-138 0.40 1.37
miR-191 0.38 1.00
miR-590 0.36 0.59
miR-339 0.36 1.77
miR-144 0.33 1.11
miR-363 0.33 3.47
miR-148a 0.31 0.29
miR-338 0.31 0.12
miR-143 0.30 0.13
miR-145 0.27 0.15
MicroRNA Fold change compared with the normal control*
AML ALL
miR-142-5p 0.24 0.20
miR-582 0.18 0.14
*The expression levels of all miRNAs in the normal control were set as one-fold.
High levels are marked in orange and low levels are marked in blue.
doi:10.1371/journal.pone.0007826.t003
Table 3. Cont.
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ALL Associated with CNS Relapse
We found four cases of ALL with subsequent CNS relapse with
one year of clinical follow-up. The miRNA expression pattern was
analyzed with SAM. The results indicated that the miRNA
expression pattern of ALL with subsequent CNS relapse was
significantlyaltered versus non-CNS relapsed ALL (Figure 2C).
There was a significant upregulation of more than 3 fold in miR-7,
miR-198 and miR-633, while miR-126, miR-345, miR-222, and miR-
551a were significantly down-regulated in ALL patients with CNS
relapse versus non-CNS relapsed ALL. The differential miRNA
expression patterns suggested that this miRNA cascade in samples
of ALL with subsequent CNS relapse may serve as a biomarker for
predicting CNS relapse in pediatric ALL. To confirm the
differential expression pattern, we performed qRT-PCR to
validate the expression of miR-126, miR-222, and miR-345 in the
validation cohort samples with or without CNS relapse (N=3 and
N=26, respectively) as shown in Figure 2D. The qRT-PCR data
confirmed the microarray results.
Prediction of Specific Risk Groups in Pediatric ALL by
MiRNA Expression Profiling
Pediatric ALL is a heterogeneous disease consisting of various
leukemia subtypes that differ markedly in their response to
chemotherapy. Accurate assignment of individual patients to
specific risk groups will aid in the planning of chemotherapy
strategies for patients. To determine whether miRNA expression
profiling of leukemic cells could identify known biological ALL-
specific risk groups, we analyzed 18 diagnostic bone marrow
samples with miRNA microarrays. Remarkably, this analysis
clearly identified three leukemia-specific risk groups that were
defined as the reference [25]. For standard risk (SR), all of the
following criteria must be fulfilled: age .1 year and ,6 years at
diagnosis; ,20,000 leukocytes/ml at diagnosis; the absence of T
cell immunology; the absence of t (9,22) or of the BCR-ABL
fusion; the absence of t (4,11) or the MLL-AF4 fusion; ,1,000
blasts/ml in peripheral blood at D8; and complete remission at
D33. For intermediate risk (IR), all of the following criteria must
be fulfilled: age ,1 year and $6 years at diagnosis; $20,000
leukocytes/ml at diagnosis; the absence of t (9,22) or the BCR-ABL
fusion; the absence of t (4,11) or the MLL-AF4 fusion; ,1,000
blasts/ml in peripheral blood at D8; and complete remission at
D33. For high risk (HR), all of the following criteria must be
fulfilled, in isolation, irrespective of age and initial leukocytes
count: blast count .1,000/ml at D8; the absence of complete
remission on D33; the presence of (9,22) or of the BCR-ABL
fusion; or the presence of t (4,11) or the MLL-AF4 fusion.
The greatest number of specific risk group-related miRNA
changes was observed in ALL patients. After the first elimination
criterion (SNR .2) was applied, only 102 of 576 miRNA
remained under consideration. Following the second elimination
criterion, the number was reduced to 49, out of which 31 were
judged as not statistically significant based on the third elimination
criterion. Thus, a total of 18 miRNA species were determined to
be abnormally regulated in specific risk groups related to miRNA
profiles (Table 5). For the standard risk group, six abnormally
expressed miRNAs were identified, four were expressed at high
levels (marked in orange) and two were expressed at low levels
(marked in blue), or the intermediate risk group, ten abnormally
expressed miRNAs were identified, eight were expressed at high
levels and two were expressed at low levels. For the high-risk
group, five abnormally expressed miRNAs were identified, three
were expressed at high levels and one was expressed at low levels.
MiRNA patterns were confirmed by qRT-PCR with selected
miRNAs using the validation cohort (Figure 3A, N=28,
including SR=5; IR=9; HR=14).
The ALL-Related MiRNA Profile is Associated with
Prednisone Response
The patient’s response to prednisone therapy is the strongest
predictor of treatment outcome in pediatric ALL. To verify
whether the molecular biomarkers could be used as a reliable
stratification factor to predict prednisone response in pediatric
ALL, we retrospectively analyzed the outcomes of 18 children with
ALL according to the presenting features and initial response to
prednisone treatment. The therapeutic effect was defined as a
reduction in the leukemic blasts in the peripheral blood to below
1000/mL after 7 days of treatment with prednisone. MiRNA
expression data showed that there were significantly different
patterns in different prednisone response groups (Figure 3B).A
unique miRNA expression signature composed of 8 genes of the
576 analyzed (miR-18a, miR-532, miR-218, miR-625, miR-193a,
miR-638, miR-550, and miR-633) can differentiate between a good
or poor prednisone response in cases of pediatric ALL. We
validated the microarray results for selected miRNAs using the
ALL validation cohort (N=24, including Good=17; Poor=7)
(Figure 3C). This suggested that miRNA expression can be
included among the markers with therapeutic significance in ALL.
The ALL-specific MiRNA Pattern is Associated with the
Prognosis and Disease Progression of Pediatric ALL
Several factors that can predict the clinical course have been
defined in CLL [26–29]. Calin and Croce described that, in
addition to its relevance as a prognostic marker, the miRNA
Table 4. Differentially expressed microRNAs in the French-
American-British (FAB) classification of AML.
MicroRNA Fold change* in the various AML subtypes
M1 M2 M3
miR-335 11.74 1.69 1.61
miR-10a 7.11 1.37 0.19
miR-100 5.05 1.33 47.21
miR-125b 2.29 1.09 18.99
miR-99a 2.72 1.21 6.73
miR-155 2.02 2.23 0.45
miR-126 0.88 2.20 0.23
miR-130 1.46 2.05 1.04
miR-146b 0.57 1.89 2.22
miR-494 0.51 0.36 2.01
miR-125a 0.30 0.34 2.46
miR-195 0.17 0.58 4.31
miR-7e 0.13 0.71 3.02
miR-551a 0.33 0.61 0.88
miR-199b 0.30 0.88 0.83
miR-29b 0.13 0.60 0.92
miR-193a 0.11 0.36 1.28
miR-142-3p 0.01 0.21 1.59
*High levels are marked in orange and low levels are marked in blue.
doi:10.1371/journal.pone.0007826.t004
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miRNA expression pattern of pediatric ALL was analyzed based
on this concept. Although currently available treatments could
cure most of the ALL patients in the 1–14 year age group, we
found that one third (6/18) of the ALL patients that underwent
miRNA profiling relapsed with one year of clinical follow-up
(Figure 3D). The miRNA expression signatures that were
identified discriminate between relapse and CR cases with at least
a two-fold change in expression. Among them, miR-7, miR-216,
and miR-100 were significantly up-regulated, while miR-486, miR-
191, miR-150, miR-487, and miR-342 were down-regulated in
relapsed patients compared with CR cases. Differentiating the
cases that relapsed within one year from the others would exactly
guide the clinical therapy and effectively improve the cure rate of
pediatric acute leukemia. The microRNA cascade of relapse may
serve as a biomarker for predicting the relapse of pediatric ALL.
To validate this conclusion further studies with a large number of
patients are required.
Putative Target Genes and Their Functions
We selected the best predicted targets for a given miRNA by
comparing information from the threebest known target predic-
tion databases: TargetScan, miRBase and PicTar. This approach
allowed us to select the common targets found by the three
different algorithms. The most significant putative targets were
listed in Table S1. By examining the Gene Ontology (GO)
database, many cancer-associated genes in biological pathways,
including apoptosis, cell proliferation, and cell migration were
found. For example, lymphoid enhancer-binding factor 1 (LEF1) was
found in ALL, selectin P ligand (SELPLG) was found in AML, and
Bax was found in prostate cancer.
Discussion
Recent studies have shown that aberrantly expressed miRNAs
are involved in cancer initiation and progression. Their expression
profiles can be used for the classification, diagnosis, and prognosis
Figure 2. MiRNA expressions in AML subtypes were validated with qRT-PCR using the validation cohort and miRNA expression
pattern associated with CNS relapse. (A) MiR-335 and miR-126 expressions in AML subtypes using the validation cohort (the p values for miR-126
were p=0.006 in M1, p=0.000 in M2 and p=0.000 in M3, respectively); (B) MiR-125b expression in AML subtypes using the validation cohort (the p
values for miR-125 were p=0.037 in M2, p=0.000 in M3, p=0.000 in M4 and p=0.002 in M5, respectively); (C) MiRNA expression pattern of pediatric
ALL associated with or without CNS relapse; (D) MiR-126 (p=0.005), miR-222 (p=0.000) and miR-345 (p=0.000) were confirmed down-regulated in
pediatric ALL patients with CNS relapse compared with non-CNS relapse using the validation cohort.
doi:10.1371/journal.pone.0007826.g002
MiRNA in Pediatric Leukemia
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microarray-based methodology has provided new insights into
the biology of a variety of adult CLL and AML [14,15,16,21].
Calin and Croce’s group revealed that miR-15a and miR-16-1 were
differentially expressed between CD5+ and CLL cells. The results
also indicated that miR-15a and miR-16-1 were associated with
prognostic factors and disease progression, and that these two
miRNAs induced apoptosis by targeting BCL2 [7,31]. Mi et al.
performed a large-scale genome-wide miRNA expression profiling
assay and identified 27 miRNAs that are differentially expressed
between ALL and AML [21]. However, the possibility of a more
accurate diagnosis of acute leukemia based on miRNAs in the
pediatric population remains to be realized. In this study, we
report the results from the miRNA expression analysis of
diagnostic leukemic blasts from pediatric patients with de novo
pediatric ALL and AML. Microarray has been proved an effective
approch to study the miRNA profiling and helpful to reveal the
potential miRNA acting as oncogene or tumor suppressor involved
in diseases progress, although there is a high risk of false discovery.
However, it is necessary to further validate every abnormal
miRNA with a large number cohort. In our study, we provided a
global miRNA expression pattern in pediatric leukemia. We did
not find abnormal expression of miR-15a and miR-16-1 in either
pediatric ALL or AML. The miRNA profiles revealed that ALL
and AML had different expression patterns of miRNAs in the
pediatric population, although they shared 17 similar expression
levels, including six miRNAs with the lowest expression levels.
Notably, we found that some miRNAs are differently expressed
between pediatric and adult cases, which reveal there exists a
pediatric–specific miRNA pattern. For example, miR-146 has been
found down-regulated in adult AML patients [15], while we found
that miR-146a was up-regulated in pediatric AML patients.
Another study showed that miR-335* (not miR-335) was down-
regulated in 27 adult AML patients [32], however, we found that
miR-335 is up-regulated in pediatric M1 patients. Li et al. found
that miR-100 was up-regulated in adult APL patients, which is the
same with pediatric APL patients in our study [33]. However, we
also found miR-100 was up-regulated in pediatric M1 patients,
which have not been reported in adult.
So far, the expression of miR-125b in adult leukemia is still not
very clear. Up-regulated miR-125b did not found in adult APL in
some studies. Bousquet et al. [34] have shown that myelodysplastic
syndrome and acute myeloid leukaemia patients carrying the
t(2;11)(p21;q23) translocation are associated with miR-125b up-
regulation, however, they only focused on 19 adult leukemia
patients carrying the t(2;11)(p21;q23) translocation and did not
study whether the expressions of miR-125b are up-regulated in
adult APL patients. Another miRNA expression profiling assay
showed miR-125b was up-regulated in 7 adult APL patients, but
this was not further validated [33]. Thus, the expression of miR-
125b needs be further examined with large-scale adult APL
patients. Our miRNA profiles and qRT-PCR confirmation
indicated that miR-125b had an abnormally high expression level
in pediatric AML, especially in the M3 subtypes. The M3 subtype
is characterized by maturation arrest at the promyelocytic stage of
development. Analysis of the relationship between miR-125b and
PML/RARA showed that the expression of miR-125b was much
higher in PML/RARA positive patients than in PML/RARA
negative patients, which suggested that miR-125b may serve as a
favorable prognosticator in M3. In a very recent paper, Bousquet
et al. [34] revealed through in vitro experiments that miR-125b was
able to interfere with primary human CD34+ cell differentiation,
and also inhibited terminal (monocytic and granulocytic) differ-
entiation in leukemic cell lines (HL60 and NB4), demonstrating
that miR-125b may block the process of differentiation.
Although most ALL patients are cured with the current
protocol-based treatments that incorporate systemic therapy, 20–
30% of the patients still die after therapy. The poor survival rate of
ALL patients is mainly due to early relapses. The management of
such patients remains unsatisfactory. Therefore, studies of
leukemia molecular pathogenesis in relapsed patients may provide
additional insights into their prognosis. We identified a special
miRNA expression pattern involved in children experiencing ALL
relapse, which included high levels of expression of miR-7, miR-
216, and miR-100 and low levels of expression of miR-486, miR-
191, miR-150, miR-487, and miR-342. Target prediction indicated
that miR-7 may be associated with a t(1;19)(q23;p13.3) chromo-
somal rearrangement in pre-B-cell acute lymphoblastic leukemia,
and that miR-216, miR-191, miR-486, and miR-487 putatively
caused the suppression of tumor suppressors (Table S1). The
mechanisms involved in the regulation of these miRNAs have yet
to be defined. In addition, we tried to get some clues about the
associations between miRNAs involved in prednisone response
and overall risk. However, no relevant expression patterns were
found between them. A potential reason is possible due to the
different definition, especially different time point for patient’s
responses (for example, for prednisone response, D8 is used for the
patient’s response to prednisone therapy, but for risk group D33 is
used.). As we all know, miRNAs have a high degree of temporal
and spatial specificity. So, it is possible that there do exist some
miRNAs which are associated with both prednisone response and
overall risk but have different expressions in these two stages. This
need to be further investigated.
Improved treatment of ALL has virtually eliminated testicular
relapse. However, control of the central nervous system (CNS)
relapse remains a therapeutic challenge in pediatric ALL [35]. In
this study, we intended to elucidate the miRNA signatures
involved in the CNS relapse of pediatric ALL. After analysis of
the miRNA profiles of ALL patients associated with CNS relapse
Table 5. MicroRNAs associated with risk categories in
pediatric ALL.
MicroRNA Fold change* in various risk factor groups**
HR IR SR
miR-210 7.04 3.78 1.17
miR-213 4.53 4.05 0.82
miR-331 2.42 3.27 1.92
miR-182 0.84 5.29 0.82
miR-144 0.69 1.32 3.37
miR-374 1.57 1.84 5.06
miR-361 1.75 4.72 1.82
miR-30d 1.89 4.68 1.82
miR-141 1.85 3.62 1.49
miR-550 0.33 1.28 0.44
miR-342 1.78 1.59 0.38
miR-125b 1.23 0.76 0.21
miR-191 1.08 2.60 0.24
miR-27a 0.72 0.41 0.82
miR-296 0.64 0.47 1.63
*High levels are marked in orange and low levels are marked in blue. **SR,
standard risk; IR, intermediate risk; HR, high risk.
doi:10.1371/journal.pone.0007826.t005
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with an expression pattern that included high expression levels of
miR-7, miR-198, and miR-663 and low expression levels of miR-
126, miR-222, miR-551a, and miR-345. The differential miRNA
expression patterns suggested that the miRNA cascade may serve
as a biomarker in the detection of early CNS relapse of pediatric
ALL. Interestingly, target prediction of the miRNA pattern
revealed that some abnormally expressed miRNAs may putatively
target neuron function- and neurotransmitter-related genes (see
Table S1). The remaining questions are what kind of roles are
played by the neuron function and neurotransmitter-related
genesin CNS leukemia and how are those genes regulated by
miRNAs? A clear picture of the regulation–function relationship
between these miRNAs and neuron function-related genes needs
to be further defined.
In conclusion, we present the results of genome-wide miRNA
expression profiling of pediatric ALL and AML from patients with
available clinical data. To our knowledge, this is the first study to
Figure 3. MiRNA expressions associated withz risk group, response to prednisone and relapse in ALL subtypes. (A) MiR-182 was highly
expressed in IR groups of ALL (p=0.000) was confirmed by qRT-PCR using the validation cohort; (B) MiRNA expression pattern of pediatric ALL
associated with responses to prednisone treatment Pediatric ALL; (C) Differentially expressed miR-18a (p=0.000) and miR-193a (p=0.001) in ALL
patients with different responses to prednisone treatment were validated by qRT-PCR using the validation cohort; (D)MiRNA expression pattern in the
relapse and non-relapse of pediatric ALL. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0007826.g003
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parameters in pediatric acute leukemia at the genome-wide level.
An obvious difference was identified between some miRNAs’
expression of pediatric and adult cases. There exists a pediatric-
specific miRNA pattern, suggesting that the spectrum of
hematopoietic malignancies between pediatric and adult patients
is significantly different. Importantly, we identified a ‘‘miRNA
cascade’’ associated with central nervous system (CNS) relapse in
ALL. Additionally, miRNA signatures associated with prednisone
response, prognosis, and disease progression of pediatric ALL were
identified.
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